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Abstract
The gene encoding eukaryotic initiation factor 5A (EIF5A) is found in diabetes-susceptibility
loci in mouse and human. eIF5A is the only protein known to contain hypusine (hydroxypu-
trescine lysine), a polyamine-derived amino acid formed post-translationally in a reaction
catalyzed by deoxyhypusine synthase (DHPS). Previous studies showed pharmacologic
blockade of DHPS in type 1 diabetic NOD mice and type 2 diabetic db/db mice improved glu-
cose tolerance and preserved beta cell mass, which suggests that hypusinated eIF5A
(eIF5AHyp) may play a role in diabetes pathogenesis by direct action on the beta cells and/or
altering the adaptive or innate immune responses. To translate these findings to human, we
examined tissue from individuals with and without type 1 and type 2 diabetes to determine
the expression of eIF5AHyp. We detected eIF5AHyp in beta cells, exocrine cells and immune
cells; however, there was also unexpected enrichment of eIF5AHyp in pancreatic polypep-
tide-expressing PP cells. Interestingly, the presence of eIF5AHyp co-expressing PP cells
was not enhanced with disease. These data identify new aspects of eIF5A biology and high-
light the need to examine human tissue to understand disease.
Introduction
The mechanisms underlying the pathogeneses of type 1 diabetes (T1D) and type 2 diabetes
(T2D) involve the activation of systemic and local inflammatory pathways, leading to eventual
dysfunction, de-differentiation and/or death of the beta cells in the pancreatic islet. Elucidating
the molecular mechanisms driving the inflammatory response is applicable to the development
of therapies for both diseases. In addition, an urgent priority in T1D research is the discovery
of biomarkers that can assist in the identification of individuals with pre-clinical disease so
early preventative therapeutic interventions can be implemented.
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Recently, our laboratories have been investigating the involvement of the hypusinated form
of eukaryotic initiation factor 5A (eIF5A) in the development and progression of diabetes in
mice. To date, eIF5A is the only known protein to contain hypusine (hydroxyputrescine
lysine) [1], which is a polyamine-derived amino acid. This post-translational modification,
formed by the process of “hypusination” [2], is catalyzed through a multi-step reaction initi-
ated by the rate-limiting enzyme deoxyhypusine synthase (DHPS) and uses the polyamine
spermidine as a cofactor to modify the Lys50 of eIF5A [2]. Previous studies using human cell
lines and yeast determined that eIF5A, the hypusinated form of eIF5A (eIF5AHyp) and DHPS
are vital for cell viability and proliferation [3,4]. Evolutionarily, eIF5A is highly conserved
including the amino acid sequence surrounding the hypusine residue, which suggests an
important role for this modification [5]. Whereas studies across species have established that
eIF5AHyp efficiently binds the ribosome complex and facilitates mRNA translation [3,6,7], the
exact function of eIF5A and eIF5AHyp remains unknown.
Interestingly, the gene encoding eIF5A is found in the Idd4 diabetes-susceptibility locus in
non-obese diabetes (NOD) mice [8,9]. In prior studies, we showed that eIF5AHyp is expressed
in the pancreatic islets of mouse [10,11], is responsible for the translation of a subset of cyto-
kine-induced transcripts in beta cells in mouse models of diabetes [12,13], and that eIF5AHyp
also appears to be required for the activation and proliferation of effector T helper cells [14].
Moreover, reducing the hypusination of eIF5A in NOD mice, a model of T1D, by pharmaco-
logical inhibition of DHPS resulted in reduced insulitis, improved glucose tolerance and pre-
served beta cell mass [14]. Similarly, pharmacological blockade of DHPS in db/db mice [15], a
model of T2D improved glucose tolerance and enhanced beta cell mass [16]. Together these
data suggest that eIF5AHyp may play a role in the pathogenesis of diabetes such that altering
the expression of eIF5AHyp may improve diabetes outcomes long-term.
To translate these findings to human, a greater understanding of eIF5AHyp in the human
pancreas and spleen is required. In particular, determining the expression pattern of eIF5AHyp
in human tissues and whether eIF5AHyp-expressing cells stratify with characteristics of disease
would be informative. In this study, we used human donor tissue samples from the Network of
Pancreatic Organ Donors with Diabetes (nPOD) (www.jdrfnpod.org) to examine the expres-
sion pattern of eIF5AHyp in the human pancreas and spleen from individuals with T1D, T2D
and non-diabetic controls.
Materials and methods
Pancreas and isolated islet cells from mouse
All mice were purchased from the Jackson Laboratory and maintained under a protocol
approved by the Indiana University School of Medicine Institutional Animal Care and Use
Committee (OLAW Assurance Number: D16-00584 (A4091-01); USDA Certificate Number:
32-R-0025; Customer ID: 798; AAALAC Unit Number: 00083; Protocol Approval #19043).
The approved method of euthanasia for mice was carbon dioxide inhalation overdose deliv-
ered using a gas cylinder, flow meter/regulator, and induction chamber; 100% CO2 delivered
at a rate such that 20–30% of the volume of the chamber is displaced per minute. This was fol-
lowed by the secondary method of cervical dislocation. Human donor tissues were collected
and provided to the investigator by the Network of Pancreatic Organ Donors with Diabetes
(https://www.jdrfnpod.org). The study was approved by the University of Florida Institutional
Review Board (IRB-1); approval #IRB201600029. Written consent was obtained.
Total pancreas and isolated islets from wildtype C57BL/6 mice as well as acinar tissue and
isolated islets from human donors (Table 1 details human donors) were subjected to immuno-
blot analysis as previously described [17]. Rabbit anti-eIF5AHyp ([13,18]; 1:1000), mouse anti-
PLOS ONE Hypusinated eIF5A in human diabetes
PLOS ONE | https://doi.org/10.1371/journal.pone.0230627 March 24, 2020 2 / 17
and analysis, decision to publish, or preparation of
the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
eIF5A (BD Biosciences; 1:2000) and guinea pig anti-insulin (DAKO; 1:5000) antibodies were
used to confirm protein expression in the pancreas.
Mice containing the RIP-cre allele (B6.CG-Tg(Ins2-cre)25Mgn/J) [19] were mated with
those containing the R26RTomato allele (B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J) [20] to
produce double transgenic animals wherein all the insulin-producing beta cells in the pancreas
expressed a fluorescent (Tomato) reporter. Pancreatic islets were isolated from RIP-cre;
R26RTomato mice and R26RTomato mice as previously described [21]. The isolated islets from all
mice were pooled together and processed for fluorescence activated cell sorting (FACS), which
facilitated the separation of islet cells into two populations: Tomato-positive beta cells and
Tomato-negative non-beta cells (which included islet cells expressing glucagon, somatostatin,
ghrelin, and pancreatic polypeptide). Pooled islets were washed with sterile PBS (Fisher Scien-
tific) and incubated in Accutase cell detachment solution (Sigma) for 10 minutes at 37C with
constant mixing (1000 rpm). Islet cells were removed from the Accutase solution by centrifu-
gation (500 x g for 1 min) and resuspended in cold buffer containing 2% BSA,1uM EDTA, and
equal parts PBS and HBSS (Fisher Scientific). The cells were filtered, collected and incubated
with APC viability dye (Zombie NIR-IR dye; BioLegend) per the manufacturer’s recom-
mended protocol. Single-cell suspensions from RIP-cre;R26RTomato mice and R26RTomato were
then sorted using an iCyt Reflection with 100 μm nozzle at 23 psi. Dead cells (NIR-IR+) were
excluded; Tomato(+) cells and Tomato(-) cells were collected into tubes containing sort buffer.
Data were analyzed using FlowJo software (Tree Star). Lysates from the two populations of
cells were subjected to immunoblot analysis. Rabbit anti-eIF5AHyp and mouse anti-eIF5A anti-
bodies were used as above, to evaluate the abundance of eIF5AHyp in the beta cell and non-
beta cell populations. Rabbit anti-Pdx1 (Chemicon; 1:1000) antibody was used to evaluate
enrichment of the beta cell (tomato+) population.
Mouse pancreas tissue and immunofluorescence analysis
Pancreas tissue was harvested from wildtype C57BL/6 mice and fixed in 4% paraformaldehyde
(Fisher Scientific), cryo-preserved using 30% sucrose, embedded in OCT (Fisher Scientific)
and sectioned onto glass microscope slides. Methods previously described for pancreas preser-
vation and immunofluorescence were followed [22]. Pancreas tissue sections (8 μm) were
stained using the following primary antibodies: guinea pig anti-insulin (DAKO; 1:500), goat
Table 1. Human donor information for islet and acinar tissue preparations.
Islet Preparation Acinar Preparation
Unique identifier SAMN11578698 UNOS AGDB487
Donor Age (years) 57.0 24
Donor Sex (M/F) M M
Donor BMI (kg/m2) 25.8 31.7
Donor HbA1c 5.7 not tested
Origin/source of islets IIDP (Integrated Islet Distribution
Program)
CORE (Center for Organ Recovery and
Education)
Islet isolation center The Scharp-Lacy Research Institute Pittsburgh (AHN)
Donor history of diabetes? Yes/
No
No No
If Yes, complete the next two lines if this information is available
Diabetes duration (years) Not Applicable Not Applicable
Glucose-lowering therapy at time
of death
Not Applicable Not Applicable
https://doi.org/10.1371/journal.pone.0230627.t001
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anti-pancreatic polypeptide (abcam; 1:200), rabbit anti-eIF5AHyp ([13,18]; 1:1000). Secondary
antibodies including Alexa-488, Cy3, or Alexa-647 (Jackson Immunoresearch) were used, fol-
lowed by DAPI (Sigma; 1:1000) to visualize nuclei. Images were acquired with a Zeiss 710 con-
focal microscope.
Human pancreas and spleen tissue
Paraffin-embedded tissue sections were obtained from the nPOD consortium (www.jdrfnpod.
org). A total of 10 nondiabetic donors, 4 donors with T2D, and 12 donors with T1D (6 autoan-
tibody positive, 6 autoantibody negative) were included in this study (Tables 2 and 3). Infor-
mation regarding donors’ demography, histology, and disease status were provided by nPOD.
The autoantibody status was also determined by nPOD as previously described [23].
Immunofluorescence analysis of human tissues
Immunofluorescent staining was performed as previously published [22] with modifications
to account for the use of paraffin embedded tissue. Briefly, tissue sections were deparaffinized
through graded ethanols (100%, 95%, 85%, 75%, 50%; Fisher Scientific) and then blocked
using normal donkey serum (Sigma). Primary antibodies used included guinea pig anti-insulin
(DAKO; 1:500), mouse anti-glucagon (Abcam; 1:500), rat anti-somatostatin (abcam; 1:200),
goat anti-pancreatic polypeptide (abcam; 1:200), goat anti-ghrelin (Santa Cruz; 1:500), mouse
anti-Pax5 (DAKO; 1:200), mouse anti-CD8 (Thermo Fisher; 1:500), mouse anti-CD4 (Leica;
1:500), rabbit anti-eIF5AHyp ([13,18]; 1:1000). Secondary antibodies including Alexa-488, Cy3,
or Alexa-647 (Jackson Immunoresearch) were used to visualize primary antibodies. DAPI
(Sigma; 1:1000) was used to visualize nuclei. Images were acquired with a Zeiss 710 confocal
microscope.
Drug treatments of cultured cells and mouse islets
HEK293T cells (ATCC #CRL-3216) were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FBS (Hyclone; Fisher Scientific), 1% Penicillin/Streptomy-
cin and 2 mM L-Glutamine. HEK293T cells were grown to 60–70% confluency on coverslips
in a 24-well plate and treated with 10 or 100 μM N1-Guanyl-1,7-diaminoheptane (GC7) [24]
(or 10 mM acetic acid; vehicle) with 0.5 mM aminoguanidine for 16 hours. Cells were fixed
with 4% paraformaldehyde in PBS and blocked for 30 min in 3% bovine serum albumin (BSA)
in PBS followed by permeabilization with 0.2% Triton X-100 in BSA-PBS for 10 min. All anti-
bodies were diluted in 3% BSA-PBS and were applied in sequential order. Cells were incubated
with rabbit anti-eIF5AHyp ([13,18], 1:1000) overnight at 4˚C followed by a one hour incubation
with anti-rabbit 488 (Jackson Immunoresearch; 1:500) at room temperature. Coverslips were
Table 2. Human donor pancreas and spleen tissue from T2D and matched controls.
nPOD case # Sample name Age (years) Gender (male/female) Ethnicity BMI T2D (yes/no) C-peptide (ng/mL) HbA1c
nPOD-6097 F1-control 43.1 female Caucasian 36.4 no 16.76 7.1
nPOD-6102 F2-control 45.1 female Caucasian 35.1 no 0.55 6.1
nPOD-6132 F1-T2D 55.8 female Hispanic 44.6 yes 0.8 9.1
nPOD-6109 F2-T2D 48.8 female Hispanic 32.5 yes <0.05 8
nPOD-6060 M1-control 24 male Caucasian 32.7 no 13.63 N/A
nPOD-6091 M2-control 27.1 male Caucasian 35.6 no 7.71 6.3
nPOD-6114 M1-T2D 42.8 male Caucasian 31 yes 0.58 7.8
nPOD-6188 M2-T2D 36.1 male Hispanic 30.6 yes 3.45 7.2
https://doi.org/10.1371/journal.pone.0230627.t002
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washed with PBS, and DAPI (Sigma; 1:1000) used to visualize nuclei. Coverslips were mounted
and images acquired with a Zeiss 710 confocal microscope.
Mouse islets were isolated as previously described [21] and subsequently cultured in RPMI
1640 media supplemented with 10% FBS (Hyclone; Fisher Scientific), and 1% Penicillin/Strep-
tomycin. Islets were treated with 100 μM GC7 (or 10 mM acetic acid; vehicle) with 0.5 mM
aminoguanidine for 72 hours; the duration of treatment to reduce hypusination was previously
determined in [10]. Islet were fixed with 4% paraformaldehyde in PBS and blocked for 1 hour
in 5% normal donkey serum (NDS) in PBS followed by permeabilization with 0.1% Triton X-
100 in NDS-PBS for 10 min. Islets were stained as described above using chambered slides;
maximum intensity projection images were processed from Z-stack image collections acquired
with a Zeiss 710 confocal microscope.
Results
Beta cell and non-beta cell distribution of eIF5AHyp in mouse
We previously developed and characterized a novel antibody that recognizes the unique
amino acid hypusine, formed exclusively through posttranslational modification of the Lys50
residue of eIF5A (eIF5AHyp) [12,18]. In this study, we utilized this antibody to investigate the







Ethnicity BMI T1D (yes/
no)
c-peptide Auto Antibodies Detected Duration of disease
(years)
nPOD-6179 1-control 21.8 female Caucasian 20.7 no 2.74 N/A N/A
nPOD-6224 1-AAb-
negative
21 female Caucasian 22.8 yes <0.05 negative 1.5
nPOD-6070 1-AAb-
positive
22.6 female Caucasian 21.6 yes <0.05 mIAA+;1A-2A+ 7
nPOD-6034 2-control 32 female Caucasian 25.2 no 3.15 N/A N/A
nPOD-6121 2-AAb-
negative
33.9 female Caucasian 18 yes 0.24 negative 4
nPOD-6143 2-AAb-
positive
32.6 female Caucasian 26.1 yes <0.05 1A-2A+;mIAA+ 7
nPOD-6229 3-control 31 female Caucasian 26.9 no 6.23 N/A N/A
nPOD-6208 3-AAb-
negative
32 female Caucasian 23.4 yes <0.05 negative 16
nPOD-6077 3-AAb-
positive
32.9 female Caucasian 22 yes <0.05 mIAA+ 18
nPOD-6015 4-control 39 female Caucasian 32.2 no 1.99 N/A N/A
nPOD-6038 4-AAb-
negative
37.2 female Caucasian 30.9 yes 0.2 negative 20
nPOD-6054 4-AAb-
positive
35.1 female Caucasian 30.4 yes <0.05 mIAA+ 30
nPOD-6055 5-control 27 male Caucasian 22.7 no 0.59 N/A N/A
nPOD-6041 5-AAb-
negative
26.3 male Caucasian 28.4 yes <0.05 negative 10
nPOD-6180 5-AAb-
positive
27.1 male Caucasian 25.9 yes <0.05 GADA+;1A-2A+; ZnT8A+;
mIAA+
11
nPOD-6104 6-control 41 male Caucasian 20.5 no 20.55 N/A N/A
nPOD-6173 6-AAb-
negative
44.1 male Caucasian 23.9 yes <0.05 negative 15
nPOD-6141 6-AAb-
positive
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expression of eIF5AHyp in mouse and human pancreas tissue and isolated islets as well as
human spleen tissue, to characterize the expression pattern of eIF5AHyp and determine if
eIF5AHyp-expressing cells stratify with characteristics of disease. To that end, we first con-
firmed the presence of eIF5AHyp in islets isolated from mouse and human pancreas as well as
in mouse pancreas and human acinar (exocrine) tissue (Fig 1A, S1 Fig).
Fig 1. Expression of hypusinated eIF5A (eIF5AHyp) in mouse and human pancreatic islets. (A) Western blot from
mouse and human pancreas tissue and isolated pancreatic islets. (B) Western blot from FACS sorted mouse islet cell
populations. (C, D) Representative immunofluorescence images of mouse tissue demonstrating robust expression of
eIF5AHyp in PP-expressing cells.
https://doi.org/10.1371/journal.pone.0230627.g001
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We next utilized the RIP-cre;R26RTomato mouse model wherein the insulin-expressing cells
were labeled with a lineage trace, thereby generating beta cells indelibly marked with fluores-
cent reporter (Tomato) expression. Islet cells from RIP-cre;R26RTomato and control animals
were sorted by FACS, using the presence and absence of Tomato expression to separate cells
into two populations: beta cells (Tomato-positive) and non-beta cells (Tomato-negative). The
cell types represented in the “non-beta cell” sample included (ordered from largest population
to smallest): glucagon-expressing alpha cells, somatostatin-expressing delta cells, pancreatic
polypeptide-expressing PP cells, ghrelin-expressing epsilon cells, exocrine cells (a possible con-
taminant from the process of islet isolation) and support cells including endothelial cells. A
similar quantity of Tomato-positive beta cells (1.92x105 cells) and Tomato-negative non-beta
cells (2.13x105 cells) were collected (S2 Fig). Subsequent western blot analysis identified that
eIF5AHyp was present in nearly identical abundance in both the beta cell (Tomato-positive)
and non-beta cell (Tomato-negative) populations (Fig 1B, S3 Fig). The expression of Pdx1 con-
firms the enrichment of beta cells in the Tomato positive cells; the lower level of Pdx1 expres-
sion in the non-beta cell fraction can be attributed to the presence of somatostatin-expressing
delta cells. These data demonstrate that eIF5AHyp is expressed in both the beta cell and non-
beta cell fractions; however, whether there is a differential expression of eIF5AHyp in a specific
non-beta cell type(s) cannot be clarified from these data. Therefore, to characterize the spatial
distribution of eIF5AHyp expression pattern in the islet, we performed co-immunofluorescence
staining for eIF5AHyp and islet hormones in mouse pancreas tissue. Whereas relatively weak
immunostaining of eIF5AHyp was found throughout the pancreas and islets, robust immunos-
taining of eIF5AHyp was found in the islet cell population that expressed pancreatic polypep-
tide (Fig 1C and 1D).
To confirm that the high expressing cell population was not an artifact and that our previ-
ously published antibody [12,18] could detect expression of eIF5AHyp by immunofluorescence,
we treated HEK293T cells (human) or isolated pancreatic islets (mouse) with the DHPS
inhibitor GC7 (N1-Guanyl-1,7-diaminoheptane) [24]. Cells and islets were then analyzed for
eIF5AHyp by immunofluorescence. Whereas the control HEK293T uniformly expressed
eIF5AHyp, the mouse islets contained cells with both weak and robust expression of eIF5AHyp.
Furthermore, following treatment with the inhibitor, we observed a reduction in expression of
eIF5AHyp in both the HEK293T cells and mouse islets compared with vehicle treated controls
(S4 Fig), which verified the measurement of eIF5AHyp expression using our antibody.
eIF5AHyp-expressing cells in the pancreas of human type 2 diabetes
To characterize the expression pattern of eIF5AHyp in the human pancreas, we utilized tissue
samples from the Network of Pancreatic Organ Donors with Diabetes (nPOD). A cohort of tis-
sues from donors with and without T2D were provided (Table 2). Both pancreas and spleen
tissues were acquired from each donor; age, gender, ethnicity and BMI were matched where
possible. Given the relatively small size of the cohort, quantitative evaluations were not possi-
ble. Therefore, we evaluated the presence or absence of eIF5AHyp, its cell-type expression pat-
tern, and its expression correlation with disease.
Pancreas tissue sections were co-immunostained with the eIF5AHyp-specific antibody and
antibodies that recognized the hormones expressed by each of the endocrine cell populations
in the islet (insulin, glucagon, somatostatin, ghrelin and pancreatic polypeptide). Robust co-
localization was not observed between eIF5AHyp and insulin (Fig 2A and 2B), glucagon (Fig
2C and 2D), ghrelin (Fig 2E and 2F), or somatostatin (Fig 2G and 2H). However, as observed
in the mouse pancreas, cells expressing pancreatic polypeptide were identified to co-express
high levels of eIF5AHyp in control pancreas tissue (Fig 3A). These cells also expressed
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chromograninA, which confirms their identity as neuroendocrine cells (Fig 3B). The co-locali-
zation of eIF5AHyp with pancreatic polypeptide in the PP-expressing cells was observed in pan-
creas tissues from donors with T2D (Fig 3C and 3D) and non-diabetic controls, suggesting no
differential expression related to disease status. Notably, whereas PP and eIF5AHyp were
expressed in the same cells, the expression pattern is suggestive of localization in different
compartments (Fig 3E).
Spleen tissue sections from the same donors were co-immunostained with eIF5AHyp and
markers of various cell types. In particular, Pax5-expressing B cells, CD4-expressing T cells,
and CD8-expressing T cells were evaluated for co-expression of eIF5AHyp. Whereas the expres-
sion patterns observed suggest that most Pax5+ B cells expressed eIF5AHyp, only a select group
of eIF5AHyp-expressing cells appear to co-expressed either CD4 or CD8 (Fig 4A–4C; S5–S7
Figs). No obvious differences in staining intensity or distribution were observed between sam-
ples from T2D and controls (Fig 4D–4E).
eIF5AHyp-expressing cells in the pancreas of human type 1 diabetes
Donor pancreas and spleen tissue from individuals with T1D were also acquired from nPOD
and evaluated for the expression pattern of eIF5AHyp. This cohort of samples included T1D
donors that were autoantibody-positive and autoantibody-negative, with both short and long
disease duration; non-diabetic controls were matched for age, gender, ethnicity and BMI
(Table 3). Similar to the T2D/control samples, we identified cells co-expressing the hormone
PP with high intensity eIF5AHyp immunostaining (Fig 5A–5F); robust co-expression of eIF5A-
Hyp with other islet hormones was not observed. Moreover, the eIF5AHyp-expressing cells
expressed ChromograninA (Fig 5G–5I), which again confirmed that these cells are neuroen-
docrine in nature. Evaluation of spleen tissue for all T1D donors and controls revealed an
identical pattern of expression to that observed in the T2D donors and controls. Specifically,
the majority of eIF5AHyp-expressing cells co-expressed Pax5 (Fig 6; S8–S10 Figs).
Fig 2. The expression pattern of eIF5AHyp in T2D and control pancreatic tissue. In controls (matched for age, gender and BMI) and
T2D pancreas, we evaluated the co-expression of eIF5AHyp with all islet hormones and found no overlap with insulin (A,B), glucagon (C,
D), ghrelin (E,F) or somatostatin (G,H).
https://doi.org/10.1371/journal.pone.0230627.g002
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Discussion
Previous data from mouse models identified that pharmacological modulation of the hypusi-
nation of eIF5A enhanced beta cell mass and improved glucose tolerance in mouse models of
both T1D and T2D [14,16], thereby suggesting an important role for eIF5AHyp in the setting of
diabetes. However, to translate these findings to human, a greater understanding of eIF5AHyp
in the human pancreas and spleen would be required. This study represents the first descrip-
tion of eIF5AHyp expression in human organs from donors with and without diabetes.
Fig 3. eIF5AHyp is robustly expressed in the pancreatic polypeptide-expressing PP cells in the islet. (A-D) In both
controls and T2D pancreas, co-expression of eIF5AHyp with pancreatic polypeptide (PP) and chromograninA (ChgA)
was observed. (E) An expression pattern of eIF5AHyp in the PP cells suggestive of localization to the ER was observed
in cells in both controls and T2D pancreas.
https://doi.org/10.1371/journal.pone.0230627.g003
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Importantly, our results reveal a heretofore unappreciated enrichment of eIF5AHyp in subsets
of endocrine cells in the pancreas and immune cells in the spleen. Interestingly, the presence
of eIF5AHyp co-expressing cells was not obviously enhanced in diseased tissue; however, larger
cohorts are required where tissue can be sampled from across whole organs in order to pre-
cisely quantitate the presence of these cells and definitively determine correlation with disease.
Further investigation is also required as to the relative abundance of the deoxyhypusine and
hypusine forms of eIF5A in both the normal and diseased setting. Currently, published work
suggests that the deoxyhypusine form of eIF5A is transient and reversible, and therefore not as
abundant due to its rapid modification by the enzyme DOHH (deoxyhypusine hydroxylase) to
the hypusinated form of eIF5A during the process of hypusine biosynthesis [25]. Our antibody
is specific for the modified forms of eIF5A over the unmodified forms [18], and the form most
detectable by our antibody due to its high prevalence is the more stable hypusinated form of
eIF5A (eIF5AHyp). Further investigation and tool development will be required to determine
and understand the relative abundance of the deoxyhypusine and hypusine forms of eIF5A in
both the normal and diseased settings.
Our findings in the pancreas demonstrate that eIF5AHyp is expressed in both the exocrine
and endocrine compartments in mouse and human. Previous reports have also shown expres-
sion of eIF5AHyp in mouse islets [10,11]. However, our immunoblot of sorted mouse islet cells
further defined that eIF5AHyp expression in the islet can be found in both the beta cell and
non-beta cell populations. The non-beta cell populations encompass multiple hormone-
Fig 4. eIF5AHyp expression pattern in the spleen of control and T2D. eIF5AHyp is expressed in immune cells in the spleen. We
evaluated expression of eIF5AHyp in Pax5+ B cells, CD4+ T cells and CD8+ T cells in the spleens of donors with T2D and controls
matched for age, gender and BMI. Most eIF5AHyp+ cells co-expressed Pax5+ (A,D); however, a select group of eIF5AHyp+ cells expressed
either CD4+ (B,E) or CD8+ (C,F).
https://doi.org/10.1371/journal.pone.0230627.g004
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expressing cell types, and our immunostaining analysis of mouse tissue clarified that the most
robust expression of eIF5AHyp is in the PP cell population. Given the over-representation of
PP cells in the uncinate region of the pancreas [26], we analyzed tissue sections that contained
the uncinate region and found that eIF5AHyp is robustly co-expressed in PP cells of human
islets. Despite evidence that PP cells have a critical secretory function in the brain-gut axis [27]
and may serve as a regulator of intra-islet secretion [28], the role of PP cells in the context of
diabetes has received little attention. From a developmental perspective, PP cells are predomi-
nantly derived from the ghrelin-expressing cell lineage found in the embryonic pancreas [29];
however, the function of eIF5AHyp in the PP cell population postnatally or any function for
eIF5AHyp in the development of PP cells has yet to be elucidated. Interestingly, expression
analysis of 12-lipoxygenase, a factor known to promote inflammation in the setting of diabetes,
Fig 5. Expression of eIF5AHyp in the T1D pancreas. (A-F) Identical to the pattern identified in T2D and control tissues, high
expression of eIF5AHyp is observed in PP cells in the T1D, both auto-antibody positive (aAb+) and auto-antibody negative(aAb-),
pancreas and controls (matched for age, gender, ethnicity and BMI). (G-I) In all cases, these cells express the endocrine cell marker
ChromograninA (ChgA).
https://doi.org/10.1371/journal.pone.0230627.g005
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is also increased in the PP-expressing cell population in pancreas tissue from human donors
(collected through nPOD; [30]). Clearly, a greater understanding is required for the role of PP
cells in the pathogenesis of diabetes.
Given that much of the published and ongoing work on hypusine biosynthesis in mice has
studied eIF5AHyp in the context of diabetes, we had hypothesized that eIF5AHyp expression
would be identified predominantly in the insulin-producing beta cell population. Our western
blot analysis did reveal eIF5AHyp expression in human islets. Moreover, we observed eIF5AHyp
expression in a purified population of beta cells (Tomato+) from mouse islets. Interestingly,
the quantitative nature of western blots indicates that the expression of eIF5AHyp must be
lower in the purified beta cells compared with non-beta cells given that PP cells comprise only
a small portion of the Tomato(-) non-beta cell fraction whereas the Tomato(+) fraction is
composed exclusively of beta cells, and we see near equivalent expression of eIF5AHyp in both
sorted populations. This finding is consistent with the immunofluorescence data, wherein we
Fig 6. Expression of eIF5AHyp in spleen tissue from donors with T1D and matched control donors. We examined
spleen tissue from persons with autoantibody positive (AAb+) and auto-antibody negative (AAb-) T1D, and
corresponding controls matched for age, gender, ethnicity, and BMI. As observed in T2D and matched control spleen
tissue, most eIF5AHyp-expressing cells were Pax5+ (A-C); however, some eIF5AHyp+ cells expressed either CD4+ (D-F)
or CD8+ (G-I).
https://doi.org/10.1371/journal.pone.0230627.g006
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identified robust expression of eIF5AHyp in PP-expressing cells. The lack of observable co-
expression of eIF5AHyp and hormones in all cell types in the islet was unexpected; however, we
must consider the possibility that this may be due to the limitations in detection of low protein
expression by immunofluorescence. Therefore, and considering all data together, our observa-
tions indicate the presence of eIF5AHyp in both beta cells and non-beta cells, with particularly
high expression in one small non-beta cell populations, the PP cells.
Our previous finding that pharmacological inhibition of eIF5A hypusination (using the
drug GC7; N1-Guanyl-1,7-diaminoheptane) in NOD mice improved glucose tolerance and
preserved beta cell mass [14]. These improvements were also accompanied by reductions in
insulitis, which led us to question whether the improvements in beta cell function were due to
a direct effect of DHPS inhibition in beta cells, or an indirect effect related to DHPS inhibition
in infiltrating immune cells. Our work and that of others suggest a role for eIF5AHyp and
DHPS in promoting T cell and B cell proliferation [14,31,32], which was the basis for our
hypothesis that perhaps eIF5AHyp is differentially expressed in immune cells in individuals
with diabetes compared with controls. However, identical expression patterns were noted in
all spleen tissue evaluated. The identical expression patterns of eIF5AHyp between healthy and
disease in both the immune cell populations and islet cell populations could also suggest that it
is not the abundance of eIF5AHyp that is critical for promotion of disease. Rather, the presence
of eIF5AHyp facilitating the translation of different mRNAs in the disease setting compared
with the healthy setting could drive pathogenesis. Given our recent findings that deletion of
Dhps in adult mouse beta cells results in reduced diet-induced beta cell proliferation and sub-
sequent glucose intolerance due to altered translation of cyclinD2 [10], we are now investigat-
ing the impact of eIF5AHyp on mRNA translation in other diabetes-related cell populations.
Supporting information
S1 Fig. Source images for western blots of mouse and human pancreas and islets.
(A) Immunoblot images show expression of eIF5AHyp, insulin and total eIF5A in cell lysates
from mouse whole pancreas and isolated islets. The top portions of these blots were proved
with antibodies not related to this study. (B) Total protein expression as visualized by Pon-
ceauS staining. (C) Immunoblot images show expression of eIF5AHyp, insulin and total eIF5A
in cell lysate from human exocrine tissue and isolated islets. One blot was probed twice, and
this second antibody was not related to this study. (D) Total protein expression as visualized
by PonceauS staining. The dotted box shows the lanes where the exocrine and islet samples
were run; the other samples are unrelated to this study.
(PDF)
S2 Fig. Collection of beta cell and non-beta cell populations by FACS. (A) Islets isolated
from multiple RIP-cre;R26RTomato mice were pooled together and processed for fluorescence
activated cell sorting (FACS). Islet cells were sorted into two populations: Tomato-positive
beta cells (R4), and Tomato-negative non-beta cells (R3, islet cells expressing glucagon,
somatostatin, ghrelin, and pancreatic polypeptide).
(PDF)
S3 Fig. Source images for western blots of FACS sorted mouse islet cell populations.
(A) Immunoblot for expression of Pdx1 and eIF5AHyp in cell lysates from Tomato-negative
non-beta cells and Tomato-positive beta cells. (B) Immunoblot for expression of total eIF5A.
(C) Total protein expression as visualized by PonceauS staining.
(PDF)
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S4 Fig. Evaluation of eIF5AHyp expression following treatment with DHPS inhibitor.
HEK293T cells were treated with the DHPS inhibitor GC7 (N1-Guanyl-1,7,diaminoheptane)
and analyzed for eIF5AHyp expression by immunofluorescence. (A) Control HEK293T cells
uniformly expressed eIF5AHyp. (B,C) Treatment with GC7 resulted in reduced expression of
eIF5AHyp. (D) A secondary antibody control was also performed to confirm that the observed
signal was not an artifact. Mouse pancreatic islets were also treated with GC7 and analyzed for
eIF5AHyp expression by immunofluorescence. (E) Control mouse islets contained cells with
both weak and robust expression of eIF5AHyp. (F, G) Islets treated with GC7 showed a reduc-
tion in expression of eIF5AHyp. Images are 20X. Inset images are higher magnification of the
areas outlined with white boxes.
(PDF)
S5 Fig. eIF5AHyp expression pattern in the Pax5-expressing cell population in spleen tissue
of control and T2D. We evaluated the expression of eIF5AHyp in Pax5-expressing B cells in
the spleens of donors with T2D and controls matched for age, gender and BMI. The fluores-
cent channels have been separated to better display the expression patterns of the Pax5-expres-
sing B cells (A, B), eIF5AHyp-expressing cells (C, D), and the overlap between the Pax5-
expressing and eIF5AHyp-expressing populations (E, F). All images are 20X.
(PDF)
S6 Fig. eIF5AHyp expression pattern in the CD4-expressing cell population in spleen tissue
of control and T2D. We evaluated the expression of eIF5AHyp in CD4-expressing T cells in
the spleens of donors with T2D and controls matched for age, gender and BMI. The fluores-
cent channels have been separated to better display the expression patterns of the CD4-expres-
sing T cells (A, B), eIF5AHyp-expressing cells (C, D), and the minimal overlap between the
CD4-expressing and eIF5AHyp-expressing populations (E, F). All images are 20X.
(PDF)
S7 Fig. eIF5AHyp expression pattern in the CD8-expressing T cell population in spleen tis-
sue of control and T2D. We evaluated the expression of eIF5AHyp in CD8-expressing T cells
in the spleens of donors with T2D and controls matched for age, gender and BMI. The fluores-
cent channels have been separated to better display the expression patterns of the CD8-expres-
sing T cells (A, B), eIF5AHyp-expressing cells (C, D), and the minimal overlap between the
CD8-expressing and eIF5AHyp-expressing populations (E, F). All images are 20X.
(PDF)
S8 Fig. eIF5AHyp expression pattern in the Pax5-expressing B cell population in spleen tis-
sue of control and T1D. We evaluated the expression of eIF5AHyp in Pax5-expressing B cells
in the spleens of donors with auto-antibody positive (AAb+) and auto-antibody negative
(AAb-) T1D, and corresponding controls matched for age, gender, ethnicity, and BMI. The
fluorescent channels have been separated to better display the expression patterns of the Pax5-
expressing B cells (A—C), eIF5AHyp-expressing cells (D—F), and the overlap between the
Pax5-expressing and eIF5AHyp-expressing populations (G—I). All images are 20X.
(PDF)
S9 Fig. eIF5AHyp expression pattern in the CD4-expressing T cell population in spleen tis-
sue of control and T1D. We evaluated the expression of eIF5AHyp in CD4-expressing T cells
in the spleens of donors with auto-antibody positive (AAb+) and auto-antibody negative
(AAb-) T1D, and corresponding controls matched for age, gender, ethnicity, and BMI. The
fluorescent channels have been separated to better display the expression patterns of the
CD4-expressing T cells (A—C), eIF5AHyp-expressing cells (D—F), and the minimal overlap
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between the CD4-expressing and eIF5AHyp-expressing populations (G—I). All images are
20X.
(PDF)
S10 Fig. eIF5AHyp expression pattern in the CD8-expressing T cell population in spleen tis-
sue of control and T1D. We evaluated the expression of eIF5AHyp in CD8-expressing T cells
in the spleens of donors with auto-antibody positive (AAb+) and auto-antibody negative
(AAb-) T1D, and corresponding controls matched for age, gender, ethnicity, and BMI. The
fluorescent channels have been separated to better display the expression patterns of the
CD8-expressing T cells (A—C), eIF5AHyp-expressing cells (D—F), and the minimal overlap
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